Douglas W. Greene

Douglas W. Greene

Lane Powell PC

Contact  |  RSS

Latest Posts › Securities

Share:

The Root Cause of Skyrocketing Securities Class Action Defense Costs

Why do the costs of defending securities class actions continue to increase? Because of my writing on the subject) I’m asked about the issue a lot. My answer has evolved from blaming biglaw economics – a combination of...more

9/10/2014 - Big Law Board of Directors Class Action Corporate Officers D&O Insurance Derivative Suit Litigation Fees & Costs Litigation Strategies Securities Securities Litigation Shareholder Litigation Shareholders

Cybersecurity Securities Class Actions are Coming: Predictions, Analysis, and Practical Guidance

Last fall, I wrote about board oversight of cybersecurity and derivative litigation in the wake of cybersecurity breaches. I plan to update my thoughts later this year, after we see developments in the recently filed Target...more

5/21/2014 - Class Action Corporate Counsel Corporate Governance Corporate Officers Cybersecurity Data Breach Derivative Suit Disclosure Requirements Risk Management Securities Securities Litigation Target Wyndham

D&O Discourse Authors Davis and Greene to File Amicus Brief in Omnicare Case

My partner Claire Loebs Davis and I are honored to be working with Washington Legal Foundation on a U.S. Supreme Court amicus brief in the Omnicare securities class action. Omnicare concerns what makes a statement of opinion...more

4/15/2014 - Board of Directors Class Action Corporate Officers D&O Insurance Omnicare SCOTUS Securities

First Take on Amgen Decision: Supreme Court “Basically” Endorses Status Quo

The Supreme Court released its anxiously awaited decision in Amgen Inc. v. Connecticut Retirement Plans yesterday. On the face of the decision, it was a loss for defendants in that case, and for companies everywhere that are...more

2/28/2013 - Amgen Amgen Inc. v Connecticut Retirement Plans Class Action Class Certification Fraud-on-the-Market Rebuttable Presumptions SCOTUS Securities Securities Fraud Securities Litigation

Looking Ahead: Forthcoming 2013 Securities and Corporate Governance Litigation Developments

This promises to be an eventful year in securities and corporate governance litigation. A number of looming developments have the potential to change the landscape for many years to come. This is the first of two posts – or...more

2/21/2013 - Amgen Books & Records Class Action Corporate Governance Derivative Suit Drug Manufacturers Scienter Section 220 Request Securities Shareholder Litigation

5 Results
|
View per page
Page: of 1